Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium Perspective
C-Path, CHDI and CDISC Announce Therapeutic Area User Guide for Huntington’s Disease TUCSON, Ariz., NEW YORK and AUSTIN, Texas, November 1, 2018 — The Huntington’s Disease Regulatory Science Consortium (HD-RSC),
FNIH Biomarkers Consortium and Critical Path Institute Achieve the First Ever Qualification of a Clinical Safety Biomarker by the U.S. Food and Drug Administration Major Milestone will Improve Detection of Drug-Induced Acute Kidney Injury in Clinical Trials. October 25, 2018 —
New Frontiers in Parkinson’s Disease: From Genetics to the Clinic Shihabuddin LS, Brundin P, Greenamyre JT, Stephenson D, Sardi SP. New Frontiers in Parkinson’s Disease: From Genetics to the
UA Colleges of Law and Pharmacy, Critical Path Institute, Launch Graduate Certificate Program in Regulatory Science Designed for graduate students and working professionals, the certificate program provides specialized training in navigating the
Best Practices for Avoiding Paper Backup When Implementing Electronic Approaches to Patient-Reported Outcome Data Collection in Clinical Trials Howry, C, E CA, Crescioni, M, E S,, O’Donohoe, P, R T,. Best Practices for Avoiding Paper Backup When Implementing Electronic Ap
Critical Path Institute and SIGNATOPE GmbH Team Up to Advance Research on Biomarkers for Drug-induced Organ Injuries TUCSON, Ariz. and REUTLINGEN, September 17, 2018 — Critical Path Institute’s Predictive Safety Testing Consortiu
June 9, 2018 Literature review to characterize the empirical basis for response scale selection in pediatric populations
June 9, 2018 Literature review to assemble the evidence for response scales used in patient-reported outcome measures